• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国政府科技报告 >Panel of Monoclonal Antibodies Which Discriminate Neuroblastoma from Ewing's Sarcoma, Rhabdomyosarcoma, Neuroepithelioma, and Hematopoietic Malignancies
【24h】

Panel of Monoclonal Antibodies Which Discriminate Neuroblastoma from Ewing's Sarcoma, Rhabdomyosarcoma, Neuroepithelioma, and Hematopoietic Malignancies

机译：从尤文氏肉瘤，横纹肌肉瘤，神经上皮瘤和造血系统恶性肿瘤中鉴别出神经母细胞瘤的单克隆抗体组

获取原文
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Neuroblastomas generally displayed strong immunoreactivity with anti-neural antibodies, but showed weak or negative binding with the remaining antibodies of the panel. Particularly striking was very weak or negative binding of antibodies against HLA-ABC, beta 2-microglobulin figronectin, and the pan-hematopoietic antigen T200. Representative antibody binding histograms for a neuroplastoma cell line are shown. In contrast to neuroblastomas, cell lines from peripheral neuroepitheliomas displayed considerable heterogeneity in their binding of anti-neural antibodies. Unlike the 'classical' neuroblastomas, antibodies to HLA-ABC, and beta-2 microglobulin bound strongly to neuroepitheliomas. The neuroepitheliomas also showed positive binding of the anti-human fibronectin antibody HFN 7.1. An atypical neuroblastoma cell line D(SK-N-MC), from a patient with a clinical history most compatible with peripheral neuroepithelioma (a chest wall primary tumor), showed the pattern of immunoreactivity of the neuroepithelioma lines.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号